C. Ola Landgren, M.D. (IMAGE) University of Miami Miller School of Medicine Caption “Today’s unanimous ODAC vote – 12-0 in favor – is a milestone for the field of multiple myeloma,” said Dr. C. Ola Landgren, director of Sylvester’s Myeloma Research Institute. “It will also set the stage for the development of novel therapies for other cancers.” Credit Photo by Sylvester Usage Restrictions None License Original content Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.